AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Combat-ready and camera-eyed: The X-Intra drone joins Israel’s arsenal
2
Tenable acquires Sam Altman-backed Apex for over $105 million to boost AI security
3
Guardicore founders raise $32 million for new stealth cyber-AI startup
4
Syte files for court protection after burning through $70 million in funding
5
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
More news

Teva

20 stories about Teva
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s quiet layoff announcement reveals bold restructuring plan

08.05.25|Sophie Shulman
CEO signals this is ‘just the first step’ in multi-year effort to streamline and scale.
מנכ"ל טבע ריצ'רד פרנסיס מפגש עיתונאים 2025

Teva to cut 3,000 jobs by 2027 in drive toward higher profit margins

07.05.25|Sophie Shulman
Pharma giant targets 30% operating margin by laying off approximately 8% of its global workforce as it boosts forecasts on drug sales and updates its "Pivot to Growth" strategy. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva signals return to fundraising after decade-long crisis

08.02.25|Sophie Shulman
Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman
Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman
Duvakitug signals a brighter future for the Israeli pharma giant. 
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman
Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.
בורסה תל אביב מסחר

How dual-listed companies boost profits without earning more

08.12.24|Uri Tal Tenne
The creative accounting tricks Israeli firms use to inflate earnings.
Noam Solomon Immunai

Immunai and Teva launch multi-tear AI collaboration for smarter drug development

14.11.24|CTech
The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.  
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
קופקסון זריקה תרופה טבע

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman
Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
ריצ'רד פרנסיס נשיא ו מנכ"ל חברת טבע

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
הנהלת מאנדיי קום MONDAY COM

How Monday overtook NICE and why Teva is on course to becoming Israel's highest-valued company

24.07.24|Sophie Shulman
While Wall Street transitions from growth stocks to value stocks, the balance of power among Israeli giants is also shifting. This reflects the speed at which the market punishes companies and rewards those leading growth processes, returning to profitability, or correctly identifying emerging fields.
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva settles $750 million tax dispute with Israeli authorities

25.06.24|Sophie Shulman
The deal with the Israel Tax Authority resolves all pending litigation related to taxes payable for the years from 2008 to 2020
ריצ'רד פרנסיס מנכ"ל טבע

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman
AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
מניית טבע בורסת ניו יורק מניה

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach
The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva expects lower profits in 2024 despite a strong Q4 performance

31.01.24|Reuters
"We are gaining momentum, and now it's about executing as we did in 2023 in 2024," said CEO Richard Francis
More Articles